The Oncology Institute Names Minh Merchant Chief Legal Officer
Rhea-AI Summary
The Oncology Institute (NASDAQ: TOI) appointed Minh Merchant as Chief Legal Officer effective April 6, 2026. Ms. Merchant will oversee legal, regulatory, compliance and privacy functions to support TOI's scaling as a national oncology platform.
She brings more than two decades of healthcare legal experience, prior general counsel roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and a JD from UCLA School of Law.
Positive
- Chief Legal Officer hire adds experienced legal leadership
- 20+ years of healthcare transactional and regulatory experience
- Prior GC roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson
- Mandate covers legal, regulatory, compliance and privacy functions
Negative
- None.
News Market Reaction – TOI
In the Apr 6 session, TOI gained 2.88%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.1% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings results | Neutral | +8.4% | Reported Q4 and full-year 2025 results with 2026 guidance and outlook. |
| Feb 26 | Earnings date set | Neutral | +4.2% | Announced timing and access details for Q4 and full-year 2025 call. |
| Feb 25 | Conference participation | Neutral | +10.8% | Outlined participation in three March 2026 healthcare investor conferences. |
| Feb 23 | Board appointment | Neutral | -0.4% | Added an experienced healthcare executive, Kim Tzoumakas, to the board. |
| Jan 12 | Guidance reaffirmed | Positive | -7.9% | Reaffirmed 2025 guidance and provided 2026 outlook with growth targets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often seen positive or neutral headlines met with mixed price reactions, including one notable selloff on reaffirmed guidance and growth outlook.
Over the last few months, TOI highlighted strong growth, with Q4 2025 revenue of $142.0M and full-year 2025 revenue of $502.7M. Guidance pointed to 2026 revenue of $630–650M and potential Adjusted EBITDA between $0–9M. The company reaffirmed its 2025 guidance and longer-term target of about 20% annual revenue growth through 2028, but that update coincided with a -7.89% move. Management and board additions in February 2026 have generally seen modest or positive reactions.
Key Terms
oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors.
Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant experience in transactional, regulatory and compliance matters. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and holds a JD from UCLA School of Law.
“We are excited to welcome Minh to TOI as our Chief Legal Officer,” said Daniel Virnich, MD, CEO of The Oncology Institute. “As our footprint and care model continue to grow, she brings the depth of experience to help TOI continue operate as a compliant and secure national oncology platform.”
“I’m thrilled at the opportunity to join TOI at this important juncture in the organization’s growth as a public company,” commented Ms. Merchant. “The organization’s mission to provide better access and affordability to cancer care is inspiring and I feel that I’m well positioned to help TOI continue its successful navigation of the rapidly evolving healthcare legal and regulatory environment.”
About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
ICR Healthcare
TOI@icrhealthcare.com
